Skip to content
Colorectal Cancer Clinical Trials

Philadelphia, Pennsylvania

Colorectal cancer clinical trials in Philadelphia, PA

48 colorectal cancer studies are recruiting participants at sites in Philadelphia as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Philadelphia at a glance

  • 48 studies are recruiting at a site in Philadelphia.
  • By phase: Early Phase 1 (1), Phase 1 (15), Phase 1/2 (11), Phase 2 (3), Phase 2/3 (1), Phase 3 (6), Phase 4 (2), No phase (2), Observational (7). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (36), university, hospital or other (12).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Philadelphia

Basic details from each study's public record (the 30 most recently updated of 48). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT05863195 · updated
  2. Decision Counseling and Follow-up for Shield+ Patients

    • Observational
    • Ages 45 to 75
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    Jefferson Center
    Registry record
    NCT07620535 · updated
  3. Shield Post-Approval Study Protocol

    • Observational
    • Ages 45 to 81
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    University of Pennsylvania
    Registry record
    NCT06880055 · updated
  4. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Sidney Kimmel Cancer Center
    Registry record
    NCT07458347 · updated
  5. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Univ of Pennsylvania, Abramson Cancer Center
    Registry record
    NCT07020221 · updated
  6. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  7. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Jefferson Torresdale Hospital · Pennsylvania Hospital · Thomas Jefferson University Hospital
    Registry record
    NCT05174169 · updated
  8. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Fox Chase Cancer Center · University of Pennsylvania
    Registry record
    NCT07213791 · updated
  9. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Fox Chase Cancer Center · Thomas Jefferson University
    Registry record
    NCT06662786 · updated
  10. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Sydney Kimmel Cancer Center
    Registry record
    NCT06720987 · updated
  11. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Fox Chase Cancer Center · Thomas Jefferson University
    Registry record
    NCT06750094 · updated
  12. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT07542704 · updated
  13. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    University of Pennsylvania
    Registry record
    NCT03526835 · updated
  14. Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

    • Early Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Fox Chase Cancer Center
    Study site
    Fox Chase Cancer Center
    Registry record
    NCT07167446 · updated
  15. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    University of Pennsylvania
    Registry record
    NCT02000089 · updated
  16. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization · University of Pennsylvania / Abramson Cancer Center
    Registry record
    NCT04657068 · updated
  17. GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Thomas Jefferson University
    Study site
    Sidney Kimmel Cancer Center at Thomas Jefferson University
    Registry record
    NCT07417488 · updated
  18. A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Criterium, Inc.
    Study site
    Thomas Jefferson University - Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06992258 · updated
  19. TCR1188-ABC Cells in KRAS-mutated Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Pennsylvania
    Study site
    University of Pennsylvania
    Registry record
    NCT07594067 · updated
  20. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407
    Registry record
    NCT07023289 · updated
  21. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study site
    University of Pennsylvania, Perelman School of Medicine
    Registry record
    NCT05919264 · updated
  22. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    Abramson Cancer Center of the University of Pennsylvania
    Registry record
    NCT04585750 · updated
  23. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #98
    Registry record
    NCT05176483 · updated
  24. DESTINY-PANTUMOUR04

    • Observational
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07124000 · updated
  25. A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07277270 · updated
  26. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Hospital of the University of Pennsylvania
    Registry record
    NCT06445062 · updated
  27. Prehabilitation in High-risk Oncologic Surgery

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Fox Chase Cancer Center
    Study site
    Fox Chase Cancer Center - Philadelphia
    Registry record
    NCT07638410 · updated
  28. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    EvolveImmune United, Inc
    Study site
    Thomas Jefferson University, Sidney Kimmel Cancer Center
    Registry record
    NCT07217171 · updated
  29. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    University of Pennsylvania
    Registry record
    NCT05059444 · updated
  30. Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

    • Phase 1
    • Ages 12 to 85
    • All sexes
    Sponsor
    Inhibrx Biosciences, Inc
    Study sites
    Children's Hospital of Philadelphia- Center for Childhood Cancer Research · University of Pennsylvania Abramson Cancer Center
    Registry record
    NCT03715933 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Philadelphia, PA on ClinicalTrials.gov.

Ask about studies near Philadelphia

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call